Shares closed at $472.95 on Wednesday, marking a second straight daily gain as the S&P 500 rose 1.46% and the Dow Jones Industrial Average gained 1.24%.
Despite the rise, the stock lagged the broader market's advance during a broadly positive trading session.
Thermo Fisher remains 26.56% below its 52-week high of $643.99 reached on 22 January, while trading volume of 1.8 million stayed below its 50-day average.
With analysts bullish but the stock lagging, what is the market missing about Thermo Fisher's true value?
How will the BIOSECURE Act reshape Thermo Fisher’s strategy in the U.S. pharmaceutical supply chain?